Xact Kapitalforvaltning AB boosted its position in shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) by 37.3% in the first quarter, HoldingsChannel.com reports. The firm owned 8,100 shares of the biotechnology company’s stock after purchasing an additional 2,200 shares during the period. Xact Kapitalforvaltning AB’s holdings in Atara Biotherapeutics were worth $322,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. JPMorgan Chase & Co. boosted its holdings in shares of Atara Biotherapeutics by 53.8% in the first quarter. JPMorgan Chase & Co. now owns 1,917,903 shares of the biotechnology company’s stock valued at $76,237,000 after buying an additional 671,216 shares during the period. Norges Bank acquired a new position in shares of Atara Biotherapeutics in the fourth quarter valued at approximately $20,648,000. Dimensional Fund Advisors LP boosted its holdings in shares of Atara Biotherapeutics by 107.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 474,973 shares of the biotechnology company’s stock valued at $16,500,000 after buying an additional 245,832 shares during the period. Canada Pension Plan Investment Board acquired a new position in shares of Atara Biotherapeutics in the fourth quarter valued at approximately $6,673,000. Finally, Deutsche Bank AG boosted its holdings in shares of Atara Biotherapeutics by 79.7% in the fourth quarter. Deutsche Bank AG now owns 221,084 shares of the biotechnology company’s stock valued at $7,678,000 after buying an additional 98,042 shares during the period.

Shares of ATRA stock opened at $21.85 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.96 and a current ratio of 9.96. The firm has a market capitalization of $1.02 billion, a PE ratio of -4.15 and a beta of 2.36. Atara Biotherapeutics Inc has a 12 month low of $21.31 and a 12 month high of $47.22.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($1.44) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.48) by $0.04. Analysts anticipate that Atara Biotherapeutics Inc will post -5.54 earnings per share for the current fiscal year.

In other Atara Biotherapeutics news, insider Joe Newell sold 1,500 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $39.96, for a total transaction of $59,940.00. Following the sale, the insider now directly owns 63,646 shares of the company’s stock, valued at $2,543,294.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Isaac E. Ciechanover sold 5,850 shares of the company’s stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $23.09, for a total transaction of $135,076.50. Following the sale, the chief executive officer now directly owns 332,243 shares in the company, valued at $7,671,490.87. The disclosure for this sale can be found here. In the last three months, insiders sold 36,150 shares of company stock worth $1,147,091. 10.60% of the stock is currently owned by insiders.

Several research firms have recently weighed in on ATRA. Citigroup upgraded shares of Atara Biotherapeutics from a “sell” rating to a “neutral” rating and upped their price target for the company from $23.00 to $24.00 in a report on Monday, June 3rd. Roth Capital started coverage on shares of Atara Biotherapeutics in a report on Thursday, May 30th. They issued a “buy” rating and a $30.00 price target for the company. Wedbush reissued an “outperform” rating on shares of Atara Biotherapeutics in a research report on Wednesday, May 29th. Stifel Nicolaus started coverage on shares of Atara Biotherapeutics in a research report on Wednesday, May 22nd. They issued a “buy” rating and a $41.00 price objective on the stock. Finally, William Blair reissued a “buy” rating on shares of Atara Biotherapeutics in a research report on Thursday, May 16th. One analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company. Atara Biotherapeutics presently has a consensus rating of “Buy” and a consensus price target of $40.40.

ILLEGAL ACTIVITY WARNING: “Xact Kapitalforvaltning AB Has $322,000 Position in Atara Biotherapeutics Inc (NASDAQ:ATRA)” was posted by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.watchlistnews.com/xact-kapitalforvaltning-ab-has-322000-position-in-atara-biotherapeutics-inc-nasdaqatra/3042582.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Read More: Range Trading

Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics Inc (NASDAQ:ATRA).

Institutional Ownership by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.